From: Mechanical stretch: physiological and pathological implications for human vascular endothelial cells
 | Cell type | Stretch intensity | Observation/Measurement | Biological process | Reference |
---|---|---|---|---|---|
1 | HUVEC | 10 % | ↑ actin | Morphology | Yoshigi et al. 2003 [29] |
2 | HUVEC | 10 % | Cells oriented 65 ° to stretch direction | Morphology | Barron et al. 2007 [32] |
3 | HUVEC | 0–110 % | Cells oriented 47.8 ° at 100 % | Morphology | Takemasa et al. 1998 [27] |
4 | HAEC | 10 % | Cells oriented at 70/90 ° | Morphology | Wang et al. 2001 [34] |
5 | HUVEC | 0–25 % | Cells oriented at 60–70 ° at 10–15 % stretch | Morphology | Haghighipour et al. 2010 [94] |
6 | HUVEC | 10 % | Perpendicular cell’s orientation | Morphology | Moretti et al. 2004 [31] |
7 | HUVEC | 20Â % | Paxillin needed for initial cell orientation | Morphology | Huang et al. 2012 [30] |
8 | BAEC | 1–10 % | Rho proteins for perpendicular alignment | Morphology | Kaunas et al. 2005 [35] |
9 | BAEC | 1–10 % | ↑ JNK (2.6-fold) at 30 min | Morphology | Kaunas et al. 2006 [36] |
10 | HUVEC | 120 % | ↑ CAMP (3-fold) | Morphology | Yamada et al. 2000 [96] |
11 | HUVEC | Local stretch by microneedle | ↑ Src homology 2-containing tyrosine phosphatase | Morphology | Ueki et al. 2009 [25] |
12 | BAEC | 5–30 % | ↑ Hsp 25 (relative activity 40 %) | Morphology | Luo et al. 2007 [38] |
↑ Hsp 70 (relative activity 60 %) | |||||
13 | BAEC | 10 % | ↑ JNK (5-fold) | Morphology | Hsu et al. 2010 [37] |
↑ ERK (4-fold) | |||||
↑ p38 (4-fold) | |||||
14 | HUVEC | 120 % | ↑ Ca2+ | Calcium influx | Naruse et al. 1998 [14] |
15 | BCE | 10/15 % | ↑ Ca2+ (2-fold) via transient receptor potential vanilloid 4 | Calcium influx | Thodeti et al. 2009 [13] |
16 | bEND | 20/35/55 % | ↑ Ca2+ via transient receptor potential channels | Calcium influx | Berrout et al. 2012 [16] |
17 | HUVEC | 20 % | ↑ c-src (3.2-fold) at 15 min | Mechanotransduction | Naruse et al. 1998 [97] |
18 | HUVEC | 20 % | ↑ pp125FAK | Mechanotransduction | Naruse et al. 1998 [98] |
19 | BAEC | 10 % | ↑ p21ras (24.7 % ratio) at 1 min | Mechanotransduction | Ikeda et al. 1999 [22] |
20 | HUVEC | 20 % | ↑ tyrosine phosphorylation (>2000 arbitrary unit) | Mechanotransduction | Katanosaka et al. 2008 [20] |
21 | BAEC | 5–25 % | ↑ ERK at 15 mins | Mechanotransduction | Shi et al. 2007 [23] |
22 | HUVEC | 120 % | ↑ integrin beta-3 (171 %) at 4 h | Adhesive | Suzuki et al. 1997 [17] |
23 | HAEC | 5–20 % | ↑ Akt phosphorylation at 5 %, 10 min (6000 arbitrary unit) | Apoptosis | Kou et al. 2009 [77] |
↑ Akt phosphorylation at 20 %, 30 min (1000 arbitrary unit) | |||||
24 | BAEC | 6–10/20 % | ↑ Akt phosphorylation and ↑ Bad phosphorylation in presence of TNFα at 6 % | Apoptosis | Liu et al. 2003 [45] |
25 | BAEC | 10 % | ↑ Akt phosphorylation at Ser 473 at 30–60 mins | Apoptosis | Nishimura et al. 2006 [78] |
26 | BAEC | 10 % | ↑ S6K phosphorylation (1.5-fold) at 30 mins | Proliferation | Li and Sumpio 2005 [1] |
27 | BAEC | 20 % | ↑ Rac1 (5-fold) | Proliferation | Liu et al. 2007 [56] |
28 | HUVEC | 20 % | ↑ c-Myc (2–3-fold) at 1–2 h | Proliferation | Hurley et al. 2010 [57] |
29 | Vein graft | 15 % | ↑ Egr-1 (5.5-fold) at 90 mins | Proliferation | Zhang et al. 2013 [58] |
 | HUVEC | 20 % | ↑ MMP-2 (3.7-fold) at 18 h | Extracellular matrix | Wang et al. 2003 [44] |
↑ MMP-14 (3-fold) at 18 h | |||||
30 | BAEC | 5 % | ↑ MMP-2 (8-fold) at 8 h | Extracellular matrix | von Offenberg Sweeney et al. 2004 [43] |
31 | BCEC | 0–28 % | ↑ pro MMP-2 | Extracellular matrix | Shukla et al. 2004 [99] |
32 | HUVEC | 15 % | ↑ MCP-1 (200 %) at 6 h | Inflammation | Demicheva et al. 2008 [100] |
33 | HUVEC | 125/150 % | ↑ IL-6 (3-fold) at 90 min | Inflammation | Kobayashi et al. 2003 [75] |
34 | HUVEC | 0–10 % | ↑ COX-2 (2.5-fold) at 3 h | Inflammation | Zhao et al. 2009 [101] |
↑ thromboxane A2 synthase (150 %) | |||||
35 | HUVEC | 120–150 % | ↑ von Willebrand factor to 5 mU/L at 60 min | Inflammation | Xiong et al. 2013 [74] |
36 | HUVEC | 6–15 % | ↑ IL-8 (2.6-fold) | Inflammation | Okada et al. 1998 [80] |
↑ MCP-1 (2.8-fold) | |||||
37 | HUVEC | 12–25 % | ↓ MCP-1 by exposure of nitric oxide donor | Inflammation | Wung et al. 2001 [102] |
38 | BAEC | 0–10 % | MMP-9 silencing block migration and tube formation | Angiogenesis | von Offenberg Sweeney et al. 2005 [55] |
39 | BAEC | 10 % | Endothelial cord aligning to 67.5–90° | Angiogenesis | Joung et al. 2006 [2] |
40 | HUVEC | 6–13 % | ↑ Ang-2 (4.8-fold) | Angiogenesis | Yung et al. 2009 [54] |
PDGF-ββ (↑ 5.0-fold) | |||||
41 | CMEC | 10 % | ↑ VEGF (1.4-fold) | Angiogenesis | Zheng et al. 2001 [51] |
42 | CMEC | 10 % | ↑ VEGF-R2 (3.2-fold) | Angiogenesis | Zheng et al. 2008 [48] |
↑ Tie-2 (1.8-fold) | |||||
43 | BAEC | 10/20 % | ↑ angiogenesis | Angiogenesis | Wilkins et al. 2014 [52] |
44 | HUVEC | 15 % | ↑ Flk-1 (1.7-fold) | Angiogenesis | Zheng et al. 2004 [47] |
↑ Tie-1 (2-fold) | |||||
↑ Tie-2 (1.9-fold) | |||||
45 | HUVEC | 10 % | ↑ Alpha smooth muscle actin (1.6-fold) | Transdifferentiation | Shoajei et al. 2014 [84] |
↑ Smooth muscle myosin heavy chain (1.3-fold) | |||||
46 | HUVEC | 10 % | ↑ Alpha smooth muscle actin (165 %) | Transdifferentiation | Cevallos et al. 2006 [83] |
↑ Caldesmon-1 (443 %) | |||||
↑ Smooth muscle myosin heavy chain (205 %) | |||||
↑ Calponin-1 (174 %) | |||||
47 | HUVEC | 10/20 % | ↑ Young’s modulus of elasticity | Stiffening | Hatami et al. 2013 [82] |
48 | BAEC | 120 % | ↑ eNOS phosphorylation (1.8 arbitrary unit) | Vascular tone | Takeda et al. 2006 [62] |
↑ NO (1.4-fold) | |||||
49 | HUVEC | 20–50 % | ↑ eNOS (7-fold) at 50 % | Vascular tone | Hu et al. 2013 [5] |
50 | HUVEC | 25 % | ↑ Et-1 (2.3-fold) | Vascular tone | Cheng et al. 2001 [4] |
51 | HUVEC | 10 % | ↑ Et-1 (1.6-fold) | Vascular tone | Toda et al. 2008 [64] |
52 | HUVEC | 6 % | ↑ 8,9-epoxyeicosatrienoic acid (EET) (4–8-fold) | Vascular tone | Fisslthaler et al. 2001 [63] |
53 | HUVEC | 100–250 % | ↑ glutathione peroxidase to 200 % | ROS | Wagner et al. 2009 [71] |
54 | HAEC | 8–20 % | ↑ p66Shc (150–200-fold) | ROS | Spescha et al. 2014 [70] |
55 | HUVEC | 5–12 % | ↓ Nox4 (40 %) 12 %, 24 h | ROS | Goettsch et al. 2009 [67] |
↑ eNOS (3-fold) at 12 %, 24 h | |||||
↑ NO (2 uM) at 5 %, 24 h | |||||
56 | HUVEC | 25 % | ↑ ROS (221 %), 6 h | ROS | Ali et al. 2004 [68] |
↑ VCAM-1 | |||||
57 | BAEC | 25 % | ↑ FAK phosphorylation | ROS | Ali et al. 2006 [66] |